TNF and macrophage activation syndrome: Given the increasing body of evidence behind the safety of TNF inhibitors in systemic autoimmune diseases, their use in pregnant patients with AoSD may be warranted, although data supporting their use as an acute or first-line treatment for MAS are lacking, and some case reports note precipitation of MAS by TNF inhibitor use [35, 36].